EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
The diagnosis and treatment of prostate cancer: a review
Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …
than 160 000 new cases each year in the United States. Although it often has an indolent …
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an …
A Pollack, TG Karrison, AG Balogh, LG Gomella… - The Lancet, 2022 - thelancet.com
Background In men with a detectable prostate-specific antigen (PSA) level after
prostatectomy for prostate cancer, salvage prostate bed radiotherapy (PBRT) results in …
prostatectomy for prostate cancer, salvage prostate bed radiotherapy (PBRT) results in …
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
CC Parker, NW Clarke, AD Cook, HG Kynaston… - The Lancet, 2020 - thelancet.com
Background The optimal timing of radiotherapy after radical prostatectomy for prostate
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non …
A Kneebone, C Fraser-Browne, GM Duchesne… - The Lancet …, 2020 - thelancet.com
Background Adjuvant radiotherapy has been shown to halve the risk of biochemical
progression for patients with high-risk disease after radical prostatectomy. Early salvage …
progression for patients with high-risk disease after radical prostatectomy. Early salvage …
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical …
P Sargos, S Chabaud, I Latorzeff, N Magné… - The Lancet …, 2020 - thelancet.com
Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre …
Background Molecular imaging is increasingly used to guide treatment decisions and
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …
[HTML][HTML] Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …
advances in imaging and molecular characterisation have resulted in multiple areas where …